tiprankstipranks
Trending News
More News >
Enovis (ENOV)
NYSE:ENOV
Advertisement

Enovis (ENOV) AI Stock Analysis

Compare
291 Followers

Top Page

ENOV

Enovis

(NYSE:ENOV)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
$31.00
▲(3.26% Upside)
Enovis' overall stock score is primarily impacted by its financial performance, which is weakened by declining revenue and profitability issues. Technical analysis provides a neutral outlook, while valuation is negatively affected by a negative P/E ratio and lack of dividend yield. The positive sentiment from the earnings call is not factored into the score due to its exclusion from the weighted calculation.
Positive Factors
Revenue Growth
The consistent revenue growth indicates strong market demand and effective execution of business strategies, supporting long-term expansion.
Margin Improvements
Improved margins suggest enhanced operational efficiency, which can lead to better profitability and competitive positioning over time.
Successful Product Launches
Successful product launches expand the company's portfolio and market presence, driving future growth and innovation in the medical technology sector.
Negative Factors
Product Launch Delays
Delays in product launches can hinder growth in key segments, affecting revenue and market competitiveness in the short to medium term.
Flat Hip and Knee Growth
Flat growth in core segments may signal challenges in market penetration and demand, impacting long-term revenue potential.
Tariff Headwinds
Tariff-related costs can strain cash flow and profitability, posing risks to financial stability and operational flexibility.

Enovis (ENOV) vs. SPDR S&P 500 ETF (SPY)

Enovis Business Overview & Revenue Model

Company DescriptionEnovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
How the Company Makes MoneyEnovis generates revenue through multiple key streams, primarily by selling medical devices and orthopedic solutions to hospitals, clinics, and healthcare professionals. The company's revenue model includes direct sales of products, as well as potential recurring revenue from post-operative care solutions and digital health services. Significant partnerships with healthcare providers and distributors enhance its market reach and facilitate the introduction of innovative products. Additionally, Enovis may engage in research and development collaborations that can lead to new product offerings and expand its revenue opportunities.

Enovis Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call for Enovis was generally positive, with strong revenue and margin growth, successful product launches, and improved financial guidance. However, there were challenges such as delays in the Arvis product launch, flat growth in the U.S. hip and knee segment, and tariff-related headwinds. Despite these setbacks, the company's overall performance and outlook are optimistic.
Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Enovis delivered reported growth of 7% and 5% on an organic constant currency basis in the second quarter of 2025. Recon business saw organic growth of 8%, and the company's revenue guidance for the year was raised by $25 million.
Improvements in Margin and Earnings
Adjusted gross margins improved by 90 basis points in the quarter and 200 basis points year-to-date. Adjusted earnings per share increased by 27% versus the prior year.
Positive Developments in Product Launches
The company reported good progress on new product launches, with the Nebula system and OrthoDrive surgical impactor receiving positive feedback from surgeons.
Successful Integration of Acquisitions
The integration of Lima has unlocked growth potential, particularly in the shoulder segment, with ARG and SMR systems driving competitive share gains.
Raised Financial Guidance
Enovis increased its revenue guidance by $25 million and raised its adjusted EBITDA range by $7 million, reflecting improved currency outlook and organic growth execution.
Negative Updates
Delays in Product Launch
The launch of the next-generation Arvis platform is delayed by six months, impacting sales in the hip and knee segments.
Challenges in Hip and Knee Growth
U.S. hip and knee growth was flat, affected by fewer selling days and headwinds in capital sales as customers deferred orders.
Tariff Headwinds
The company faced $6 million in tariff costs in Q2, impacting cash flow. The tariff situation remains fluid, and future impacts are uncertain.
Company Guidance
During Enovis' second-quarter 2025 earnings call, the company announced several key financial metrics and provided updated guidance. Enovis reported a 7% increase in sales to $565 million, with organic growth of 5%. Their Recon business achieved 8% organic growth, while P&R grew by 3%. Adjusted gross margins expanded by 90 basis points in the quarter, with a 200 basis point improvement year-to-date. Adjusted EBITDA was flat at 17.2%, with year-to-date expansion of 75 basis points. The company raised its revenue guidance to a range of $2.245 billion to $2.275 billion, driven by improved currency outlooks and strong organic growth execution. Organic growth guidance was increased to 6.25% to 6.75%, and adjusted earnings per share guidance was increased by $0.10 to a range of $3.05 to $3.20. Enovis also reiterated its expectation for positive free cash flow in 2025, with a focus on reducing debt and improving leverage.

Enovis Financial Statement Overview

Summary
Enovis is facing significant financial challenges, with declining revenue and profitability issues. While there are improvements in leverage, the company struggles with cash flow generation. The strong gross profit margin indicates operational efficiency, but overall financial health is weakened by ongoing losses and cash flow difficulties.
Income Statement
45
Neutral
Enovis has experienced a decline in revenue, with a negative revenue growth rate of -19.77% in the TTM period. The company is facing challenges with profitability, as indicated by negative net profit and EBIT margins. The gross profit margin remains relatively strong at 69.79%, suggesting some operational efficiency. However, the overall financial health is impacted by significant losses.
Balance Sheet
55
Neutral
The debt-to-equity ratio has improved significantly in the TTM period, indicating better leverage management. However, the return on equity is negative, reflecting ongoing profitability challenges. The equity ratio remains stable, suggesting a solid asset base relative to equity.
Cash Flow
40
Negative
The cash flow situation is concerning, with a significant decline in free cash flow growth and negative free cash flow in the TTM period. The operating cash flow to net income ratio is positive, indicating some ability to generate cash from operations despite net losses. However, the free cash flow to net income ratio is negative, highlighting cash flow challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.19B2.11B1.71B1.56B1.43B1.12B
Gross Profit1.30B1.18B990.78M869.38M657.88M1.14B
EBITDA-460.10M-481.03M169.92M225.78M248.21M180.05M
Net Income-827.47M-825.49M-33.26M-14.99M71.66M42.63M
Balance Sheet
Total Assets5.02B4.72B4.51B4.27B8.52B7.35B
Cash, Cash Equivalents and Short-Term Investments44.07M48.17M36.19M24.30M680.25M101.07M
Total Debt1.46B1.40B536.42M334.82M2.16B2.41B
Total Liabilities2.44B2.15B1.09B823.45M3.85B3.76B
Stockholders Equity2.58B2.56B3.42B3.45B4.62B3.54B
Cash Flow
Free Cash Flow-3.95M-67.21M12.77M-161.31M251.86M187.15M
Operating Cash Flow188.06M113.50M134.99M-55.86M356.10M301.94M
Investing Cash Flow-226.63M-955.47M-242.47M-176.39M-320.48M-175.08M
Financing Cash Flow37.19M846.82M127.80M-465.13M584.91M-131.65M

Enovis Technical Analysis

Technical Analysis Sentiment
Negative
Last Price30.02
Price Trends
50DMA
29.67
Positive
100DMA
31.34
Negative
200DMA
36.15
Negative
Market Momentum
MACD
0.51
Positive
RSI
50.00
Neutral
STOCH
28.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENOV, the sentiment is Negative. The current price of 30.02 is below the 20-day moving average (MA) of 31.61, above the 50-day MA of 29.67, and below the 200-day MA of 36.15, indicating a neutral trend. The MACD of 0.51 indicates Positive momentum. The RSI at 50.00 is Neutral, neither overbought nor oversold. The STOCH value of 28.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENOV.

Enovis Risk Analysis

Enovis disclosed 44 risk factors in its most recent earnings report. Enovis reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Enovis Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
1.76B50.523.83%0.69%-5.41%17.47%
71
Outperform
2.18B24.8620.33%0.10%2.82%7.50%
69
Neutral
2.44B43.637.84%0.63%9.64%-24.68%
54
Neutral
2.75B-44.83-22.78%20.19%-12.34%
52
Neutral
1.70B-91.78-1.19%3.86%-7.93%91.44%
49
Neutral
$1.79B-28.31%14.40%-662.25%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ENOV
Enovis
30.02
-13.35
-30.78%
EPAC
Enerpac Tool Group
39.71
-1.96
-4.70%
HI
Hillenbrand
23.33
-2.95
-11.23%
SXI
Standex International
201.74
20.48
11.30%
HLIO
Helios Technologies
52.50
6.84
14.98%
XMTR
Xometry
55.02
36.51
197.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 24, 2025